Deferasirox Mylan

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to **EPAR - Procedural steps taken and scientific information after authorisation (archive)**.

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
Variation type IB /	C.I.2 Change(s) in the Summary of Product	26/09/2025		SmPC	To update Section 4.2 of the SmPC to include

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

EMA/VR/0000295411	Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (Type IB) – To update Section 4.2 of the SmPC to include information on posology based on the noninterventional study CICL670A2429. This was a survey to assess physicians' knowledge of the posology and biological monitoring recommendations as described in the Educational Materials of the reference product Exjade. The change follows assessment of the same change for the reference product Exjade. In addition, the MAH took the opportunity to implement editorial changes to the PI in BG, DK, RO and SK to align with the PI of the reference product, to correct typographic and grammatical errors and to align with the QRD template.				information on posology based on the noninterventional study CICL670A2429. This was a survey to assess physicians' knowledge of the posology and biological monitoring recommendations as described in the Educational Materials of the reference product Exjade. The change follows assessment of the same change for the reference product Exjade.
Variation type IB / EMA/VR/0000268655	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.e) Container closure system - B.II.e.z Other variation - Accepted	10/07/2025	N/A		

Variation type IA / EMA/VR/0000268284	This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted	30/04/2025		Annex II and PL	